In the largest clinical trial of Kisqali (ribociclib) for advanced breast cancer, patients who took the drug lived a median of about 12 months longer than those on hormone therapy alone: 63.9 months versus 51.4 months. That’s roughly five years and four months compared to four years and three months. The size of that benefit varies depending on your age, menopausal status, and whether Kisqali is your first treatment or a later one.
Survival in Postmenopausal Women
The clearest survival data comes from the MONALEESA-2 trial, which enrolled postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer receiving Kisqali as their first treatment. Women who took Kisqali alongside the hormone therapy letrozole had a median overall survival of 63.9 months. Women on letrozole alone lived a median of 51.4 months. That translates to a 24% reduction in the risk of death.
Median survival is the point at which half the patients in a group are still alive. It doesn’t tell you exactly how long any one person will live, but it’s the most reliable way to compare two treatments head to head. In this case, the difference of roughly one year was statistically significant, meaning it’s very unlikely to be a fluke of chance.
Survival in Premenopausal Women
Younger women saw a similar benefit. The MONALEESA-7 trial enrolled 672 pre- and perimenopausal women with advanced HR-positive, HER2-negative breast cancer. Those who received Kisqali plus hormone therapy had a median overall survival of 58.7 months, compared to 48.0 months for hormone therapy alone. That’s nearly 11 additional months, with the same 24% reduction in the risk of death seen in the postmenopausal trial.
This was a landmark result because it was the first time any CDK4/6 inhibitor, the drug class Kisqali belongs to, demonstrated a clear overall survival advantage in younger women with this type of breast cancer.
Survival When Used as a Second Treatment
Some patients start Kisqali after their cancer has already progressed on an earlier hormone therapy. In the MONALEESA-3 trial, which paired Kisqali with the hormone drug fulvestrant, results depended on whether patients were being treated for the first time or had already tried another therapy.
For first-line patients, the benefit was substantial: a 36% reduction in the risk of death. Most patients in the Kisqali group were still alive when the data were analyzed, so researchers couldn’t pin down an exact median survival number for them, but the comparison group had a median of 51.8 months.
For second-line patients, the gains were more modest. Median survival was 39.7 months with Kisqali versus 33.7 months without it, a difference of about six months. The statistical confidence around this number was weaker, meaning the benefit is likely real but less certain in size.
Kisqali for Early-Stage Breast Cancer
Since 2024, Kisqali has also been approved for a different situation entirely: early-stage breast cancer that has been surgically removed but carries a high risk of coming back. In this setting, the goal isn’t extending survival in advanced disease. It’s preventing recurrence.
The NATALEE trial enrolled over 5,000 patients with stage II or III HR-positive, HER2-negative early breast cancer. Adding Kisqali to standard hormone therapy for three years reduced the risk of the cancer returning by 25%. This trial hasn’t yet shown a difference in overall survival, which takes longer to measure, but the reduction in recurrence is meaningful. The dose used for early breast cancer is lower (400 mg daily) than the dose for advanced disease (600 mg daily), both taken on a three-weeks-on, one-week-off cycle.
How Kisqali Works
Cancer cells need to copy their DNA before they can divide. Kisqali blocks two proteins, CDK4 and CDK6, that act as a green light for that copying process. By shutting those proteins down, the drug traps cancer cells in a holding pattern where they can’t progress toward division. It’s taken as a daily pill for 21 consecutive days, followed by seven days off, repeating in 28-day cycles. It’s always paired with hormone therapy because the two approaches attack the cancer through different pathways.
Side Effects and What to Expect
The most common side effect is a drop in white blood cells called neutropenia, which occurred in about 74% of patients across clinical trials. Severe drops happened in roughly 58% of patients. This sounds alarming, but it’s typically managed with dose adjustments and rarely causes infections that need hospitalization. Your care team will monitor your blood counts frequently, especially during the first few months.
Liver enzyme elevations are the second concern. Across trials, about 10% of patients had significant increases in one liver marker and 7% had increases in another. These elevations are usually caught on routine blood work before they cause symptoms, and they typically reverse when the dose is reduced or paused.
A smaller but important risk involves heart rhythm changes. About 1% of patients developed a prolonged QTc interval on their electrocardiogram, a measure of how long the heart takes to reset between beats. A prolonged interval can, in rare cases, trigger dangerous heart rhythms. Because of this, you’ll have electrocardiograms at the start of treatment and periodically throughout.
Quality of Life on Treatment
Living longer only matters if those extra months are worth living. Across the MONALEESA trials, researchers tracked patient-reported quality of life every 8 to 12 weeks using standardized questionnaires. Patients on Kisqali did not experience a faster decline in their overall health status or quality of life compared to those on hormone therapy alone. In practical terms, the survival gains weren’t coming at the cost of feeling significantly worse day to day, though the questionnaires don’t capture every possible symptom.
Putting the Numbers in Context
A median survival extension of 10 to 12 months in advanced breast cancer is a clinically meaningful result. But it’s important to understand what these numbers can and can’t tell you. Medians describe the middle of a group, not any individual. Some patients live far longer than the median, and some shorter. Your own outcome depends on factors like how widespread the cancer is, how well it responds to hormone therapy, your overall health, and how you tolerate treatment.
The hazard ratio, a number used across all the trials, was consistently around 0.76. That means at any given point during the study, patients on Kisqali were about 24% less likely to die than those on hormone therapy alone. That benefit held across both age groups and in both first-line treatment settings.
For patients with early-stage disease, the question is different. The 25% reduction in recurrence risk doesn’t translate directly into months of extra life yet, but keeping cancer from returning is the most effective way to improve long-term survival. Those results will continue to mature over the coming years as follow-up data accumulate.